Screener
Aquestive Therapeutics, Inc. AQST Co-development and research fees — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Manufacture and supply revenue | $11,911 | $9,583 | $20,704 | $16,776 |
| License and royalty revenue (a) | 1,326 | 839 | 6,721 | 1,629 |
| Co-development and research fees | 582 | 378 | 840 | 796 |
| Proprietary product revenue, net | — | (797) | — | (478) |
| Total revenues | $13,819 | $10,003 | $28,265 | $18,723 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s co-development and research fees — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported co-development and research fees — revenue of $582K in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s co-development and research fees — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s co-development and research fees — revenue increased by 54.0% year-over-year, from $378K to $582K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s co-development and research fees — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s co-development and research fees — revenue has grown at a -6.0% compound annual growth rate (CAGR), from $1.64M to $1.28M.
- What does co-development and research fees — revenue mean?
- This metric represents the revenue recognized from collaborative research and development arrangements, including milestone payments or service fees earned through partnerships. It reflects the company's ability to monetize its proprietary technology platforms and intellectual property by assisting third parties in drug development. This revenue stream is a key indicator of the company's strategic partnerships and its success in leveraging internal R&D capabilities to generate non-dilutive capital.
Ask your AI about Aquestive Therapeutics, Inc.'s co-development and research fees — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude